National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Adult Primary Liver Cancer Treatment (PDQ®)
Patient VersionHealth Professional VersionEn españolLast Modified: 03/03/2008



Purpose of This PDQ Summary






General Information






Cellular Classification







Stage Information






Localized Resectable Adult Primary Liver Cancer






Localized and Locally Advanced Unresectable Adult Primary Liver Cancer






Advanced Adult Primary Liver Cancer






Recurrent Adult Primary Liver Cancer






Get More Information From NCI






Changes to This Summary (03/03/2008)






More Information



Page Options
Print This Page  Print This Page
Print This Document  Print Entire Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate

New Study of Targeted Therapies for Breast Cancer

The Nation's Investment in Cancer Research FY 2009

Cancer Trends Progress Report: 2007 Update

Past Highlights
You CAN Quit Smoking Now!
Stage Information

TNM Definitions
AJCC Stage Groupings
Localized resectable Adult Primary Liver Cancer
Localized and locally advanced Unresectable Adult Primary Liver Cancer
Advanced Adult Primary Liver Cancer

The American Joint Committee on Cancer (AJCC) has designated TNM stages for liver cancer as follows:[1]

TNM Definitions

Primary tumor (T)

  • TX: Primary tumor cannot be assessed
  • T0: No evidence of primary tumor
  • T1: Solitary tumor without vascular invasion
  • T2: Solitary tumor with vascular invasion or multiple tumors none more than 5 cm
  • T3: Multiple tumors more than 5 cm or tumor involving a major branch of the portal or hepatic vein(s)
  • T4: Tumor(s) with direct invasion of adjacent organs other than the gallbladder or with perforation of the visceral peritoneum

Regional lymph nodes (N)

  • NX: Regional lymph nodes cannot be assessed
  • N0: No regional lymph node metastasis
  • N1: Regional lymph node metastasis

 [Note: The regional lymph nodes are the hilar (i.e., those in the hepatoduodenal ligament, hepatic, and periportal nodes). Regional lymph nodes also include those along the inferior vena cava, hepatic artery, and portal vein. Any lymph node involvement beyond these nodes is considered distant metastasis and should be coded as M1. Involvement of the inferior phrenic lymph nodes should also be considered M1.]

Distant metastasis (M)

  • MX: Distant metastasis cannot be assessed
  • M0: No distant metastasis
  • M1: Distant metastasis

 [Note: Metastases occur most frequently in bones and lungs. Tumors may extend through the capsule to adjacent organs (adrenal glands, diaphragm, and colon) or may rupture, causing acute hemorrhage and peritoneal carcinomatosis.]

The T classification is based on the results of multivariate analyses of factors affecting prognosis after resection of liver carcinomas. The classification considers the presence or absence of vascular invasion (as assessed radiographically or pathologically), the number of tumor nodules (single vs. multiple), and the size of the largest tumor (≤ 5 cm vs. > 5 cm). For pathologic classification, vascular invasion includes gross as well as microscopic involvement of vessels. Major vascular invasion (T3) is defined as invasion of the branches of the main portal vein (right or left portal vein; this does not include sectoral or segmental branches) or as invasion of one or more of the 3 hepatic veins (right, middle, or left). Multiple tumors include satellitosis, multifocal tumors, and intrahepatic metastases. Invasion of adjacent organs other than the gallbladder or with perforation of the visceral peritoneum is considered T4.

AJCC Stage Groupings

Stage I

  • T1, N0, M0

Stage II

  • T2, N0, M0

Stage IIIA

  • T3, N0, M0

Stage IIIB

  • T4, N0, M0

Stage IIIC

  • Any T, N1, M0

Stage IV

  • Any T, any N, M1

For purposes of treatment, patients with liver cancer are grouped into 1 of 3 groups: localized resectable, localized unresectable, or advanced disease. These groups are described with the following AJCC stage groupings:

Localized resectable Adult Primary Liver Cancer

(Selected T1 and T2; N0; M0)

Localized resectable liver cancer is confined to a solitary mass in a portion of the liver, or a limited number of tumors confined to one lobe, that allows the possibility of complete surgical removal of the tumor with a margin of normal liver. Liver function tests are usually normal or minimally abnormal, and there should be no evidence of cirrhosis beyond Child class A or chronic hepatitis. Only a small percentage of liver cancer patients will prove to have such localized resectable disease. Preoperative assessment that includes 3-phase helical computed tomography and/or magnetic resonance scanning should be directed toward determining the presence of extension of tumor across interlobar planes, involvement of the hepatic hilus, or encroachment on the vena cava. A resected specimen should ideally contain a 1 cm margin of normal liver.

Localized and locally advanced Unresectable Adult Primary Liver Cancer

(Selected T1, T2, T3, and T4; N0; M0)

Localized and locally advanced unresectable liver cancer appears to be confined to the liver, but surgical resection of the entire tumor is not appropriate because of location within the liver or concomitant medical conditions (such as cirrhosis). These patients may be considered for liver transplantation.[2-5] For other patients, percutaneous ethanol injection, radiofrequency ablation, or chemoembolization may be options.[6]

Advanced Adult Primary Liver Cancer

(Any T, N1 or M1)

Advanced liver cancer is present in both lobes of the liveror has metastasized to distant sites. Median survival is usually 2 to 4 months. The most common metastatic sites of hepatocellular cancer are the lungs and bone. Multifocal disease in the liver is common, particularly when cirrhosis or chronic hepatitis is present. Chemoembolization has been beneficial in selected patients who have no extrahepatic metastases.[6]

References

  1. Liver (including intrahepatic bile ducts). In: American Joint Committee on Cancer.: AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer, 2002, pp 131-8. 

  2. Farmer DG, Rosove MH, Shaked A, et al.: Current treatment modalities for hepatocellular carcinoma. Ann Surg 219 (3): 236-47, 1994.  [PUBMED Abstract]

  3. Ringe B, Wittekind C, Weimann A, et al.: Results of hepatic resection and transplantation for fibrolamellar carcinoma. Surg Gynecol Obstet 175 (4): 299-305, 1992.  [PUBMED Abstract]

  4. Venook AP: Treatment of hepatocellular carcinoma: too many options? J Clin Oncol 12 (6): 1323-34, 1994.  [PUBMED Abstract]

  5. Iwatsuki S, Starzl TE, Sheahan DG, et al.: Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 214 (3): 221-8; discussion 228-9, 1991.  [PUBMED Abstract]

  6. Tanaka K, Nakamura S, Numata K, et al.: The long term efficacy of combined transcatheter arterial embolization and percutaneous ethanol injection in the treatment of patients with large hepatocellular carcinoma and cirrhosis. Cancer 82 (1): 78-85, 1998.  [PUBMED Abstract]

Back to TopBack to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov